Halozyme Therapeutics vs Qiagen: revenue, profit, margins and growth compared
Halozyme Therapeutics brought in $1.4B of revenue in fiscal 2025, Qiagen $2.1B in fiscal 2025. Revenue changed by +37.6% at Halozyme Therapeutics and +5.7% at Qiagen on the year before, so Halozyme Therapeutics grew faster. Halozyme Therapeutics kept 22.7% of its revenue as net profit, Qiagen 20.3%. Free cash flow was $644.6M at Halozyme Therapeutics and $453.3M at Qiagen.
Fiscal years as each company reports them; the two may end in different months.
Questions about Halozyme Therapeutics and Qiagen
Which is bigger by revenue, Halozyme Therapeutics or Qiagen?
Qiagen is bigger by revenue: $2.1B in fiscal 2025, against $1.4B for Halozyme Therapeutics in fiscal 2025.
Which keeps more of its revenue as profit, Halozyme Therapeutics or Qiagen?
Halozyme Therapeutics had a net margin of 22.7% in fiscal 2025; Qiagen had 20.3% in fiscal 2025.
Which grew revenue faster, Halozyme Therapeutics or Qiagen?
In their latest fiscal years revenue changed by +37.6% at Halozyme Therapeutics and +5.7% at Qiagen.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.